Apollomics, Inc. APLM

APLM Company Overview

Apollomics, Inc. (NASDAQ: APLM) is a clinical-stage biopharmaceutical company focused on the development of precision oncology therapies targeting genetically defined cancers. The company operates within the biotechnology and pharmaceutical research industry, with a primary emphasis on small-molecule targeted therapies for oncology indications. Its business model centers on advancing internally developed drug candidates through clinical trials and, where appropriate, pursuing regulatory approval and commercialization through partnerships.

The company’s core pipeline targets cancer-driving molecular pathways, with its most advanced programs addressing solid tumors such as non-small cell lung cancer and other malignancies with high unmet medical need. Apollomics positions itself as a cross-border oncology developer with integrated operations in both the United States and China, enabling access to broader patient populations and clinical development efficiencies. The company traces its origins to its founding in 2015 and became publicly listed in 2022 through a business combination, evolving from a privately held research-focused entity into a publicly traded clinical-stage company.